Literature DB >> 15168159

Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis.

Yasuhiro Shimojima1, Takahisa Gono, Kanji Yamamoto, Kenichi Hoshi, Masayuki Matsuda, Kunihiro Yoshida, Shu-ichi Ikeda.   

Abstract

We report a patient with polymyositis (PM) associated with myasthenia gravis (MG). Both disorders had been controlled for around 15 years by oral prednisolone and a cholinesterase inhibitor following surgical removal of invasive thymoma and radiotherapy, but muscular weakness due to myalgia and an increase in serum levels of myogenic enzymes, mainly ascribable to the recurrence of PM, reappeared immediately after cessation of these drugs, which was done because the patient had multiple bone fractures and severe osteoporosis due to the long-term corticosteroid therapy. Oral tacrolimus was therefore tried, and produced an improvement in muscular symptoms in association with normalization of myogenic enzymes. PM associated with MG as in this patient might be the best indication for tacrolimus, considering its efficacy in MG, but this drug should also be actively considered as a therapeutic option in refractory cases of PM alone, particularly when either corticosteroids or other immunosuppressive agents are not usable.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168159     DOI: 10.1007/s10067-004-0865-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  26 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Inflammatory myopathies: how to treat the difficult cases.

Authors:  F L Mastaglia; P J Zilko
Journal:  J Clin Neurosci       Date:  2003-01       Impact factor: 1.961

3.  Unicorns, dragons, polymyositis, and other mythological beasts.

Authors:  Anthony A Amato; Robert C Griggs
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

4.  Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases.

Authors:  M Duddridge; R J Powell
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

5.  Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.

Authors:  Patrick Cherin; S Pelletier; A Teixeira; P Laforet; T Genereau; A Simon; T Maisonobe; B Eymard; S Herson
Journal:  Arthritis Rheum       Date:  2002-02

6.  Myasthenia gravis and associated autoimmune diseases.

Authors:  M T Palmisani; A Evoli; A P Batocchi; E Bartoccioni; P Tonali
Journal:  Muscle Nerve       Date:  1994-10       Impact factor: 3.217

Review 7.  Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.

Authors:  K A Qushmaq; A Chalmers; J M Esdaile
Journal:  J Rheumatol       Date:  2000-12       Impact factor: 4.666

Review 8.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

9.  Polymyositis: an overdiagnosed entity.

Authors:  M F G van der Meulen; I M Bronner; J E Hoogendijk; H Burger; W J van Venrooij; A E Voskuyl; H J Dinant; W H J P Linssen; J H J Wokke; M de Visser
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

10.  Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells.

Authors:  Kimiaki Utsugisawa; Yuriko Nagane; Hisashi Yonezawa; Daiji Obara; Ryushi Kondoh; Hideo Tohgi
Journal:  Muscle Nerve       Date:  2003-02       Impact factor: 3.217

View more
  6 in total

1.  Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

Review 2.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

Review 3.  The emerging role of tacrolimus in myasthenia gravis.

Authors:  Jennifer L Cruz; Marissa L Wolff; Adam J Vanderman; Jamie N Brown
Journal:  Ther Adv Neurol Disord       Date:  2015-03       Impact factor: 6.570

Review 4.  The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review.

Authors:  Yongpeng Ge; Hang Zhou; Jingli Shi; Bin Ye; Qinglin Peng; Xin Lu; Guochun Wang
Journal:  Clin Rheumatol       Date:  2015-09-02       Impact factor: 2.980

5.  Treatment of refractory juvenile dermatomyositis with tacrolimus.

Authors:  Jihaan Hassan; Jan Jaap van der Net; Annet van Royen-Kerkhof
Journal:  Clin Rheumatol       Date:  2008-08-21       Impact factor: 2.980

6.  Reversible spontaneous EMG activity during myasthenic crisis: Two case reports.

Authors:  Theocharis Tsironis; Santiago Catania
Journal:  eNeurologicalSci       Date:  2018-11-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.